Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

The Indianapolis-based drugmaker reported revenue of $19.3 billion — up 43% from the same period a year ago, driven by growth ...

The American maker of Mounjaro has struck a decisive blow against its European rival behind Ozempic and Wegovy as the battle ...

Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results ...

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

Eli Lilly’s Q4 beat and bullish 2026 guidance highlight GLP-1 strength from Mounjaro/Zepbound, supporting a $1240–1300 target ...

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has ...

Pharmaceutical giant Eli Lilly (LLY) has reported fourth-quarter 2025 financial results that blew past Wall Street forecasts.

Eli Lilly and Co (LLY) reports a 45% increase in full-year revenue, driven by key product launches and strategic expansions, ...

The rally in Lilly also pressured shares of its main weight-loss rival, Danish drugmaker Novo Nordisk ( NVO ), for a second ...

Eli Lilly (LLY) stock rises after Q4 2025 earnings beat and strong 2026 outlook following a drop led by an underwhelming ...